Skip to main content

Table 3 Duration of statin use and the risk of gastric cancer in diabetic patients

From: Statins and the risk of gastric cancer in diabetes patients

univariable analysis

Variable (Statin duration)

Case

Control

P-value+

OR (95% CI)+

0.5-1.0

38

71

< .0001

0.375 (0.216 – 0.651)

1.0-1.5

12

61

< .0001

0.138 (0.059 – 0.319)

1.5-2.0

13

41

< .0001

0.152 (0.058 – 0.400)

≥2.0

36

194

< .0001

0.132 (0.080 – 0.219)

multivariable analysis

Variable (Statin duration)

Case

Control

P-value

OR (95% CI)

0.5-1.0

38

71

0.0016+

0.446 (0.252 – 0.790) +

1.0-1.5

12

61

< .0001+

0.143 (0.061 – 0.338) +

1.5-2.0

13

41

< .0001+

0.178 (0.067 – 0.474) +

≥2.0

36

194

< .0001+

0.154 (0.091 – 0.260) +

Aspirin

184

347

< .0001

0.618 (0.454 – 0.843)

Other lipid lowering agents

154

221

< .0001

0.144 (0.053 – 0.392)

  1. (reference category: Unexposed group).
  2. Conditional logistic regression analysis was used.
  3. + ; Bonferroni’s correction was used to adjust inflation type I error due to multiple testing.
  4. (reference category: Unexposed group).
  5. Conditional multiple logistic regression analysis was used.
  6. + ; Multiple conditional logistic regression with Bonferroni’s correction.
  7. *Abbreviations: OR odds ratio.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us